Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.
Dr. Patrick Wen
Advertisement
Articles by Dr. Patrick Wen
The accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation, is a step in the right direction but more work remains.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Why Multidisciplinary Care is Crucial in Prostate Cancer
2
Enhertu Improves Invasive Disease-Free Survival in HER2+ Early Breast Cancer
3
Real-World vs Clinical Trial Biomarker Testing in Early-Stage NSCLC
4
The Importance of Awareness and Self-Advocacy in Multiple Myeloma
5
